CompletedPHASE1, PHASE2NCT00244361
Effectiveness of Rituximab in Pediatric OMS Patients.
Studying Opsoclonus-myoclonus syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Pediatric Neuroinflammation Organization, Inc.
- Principal Investigator
- Michael R Pranzatelli, M.D., MDNational Pediatric Neuroinflammation Organization, Inc.
- Intervention
- rituximab(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 19 years · All sexes
- Timeline
- 2005 – 2007
Study locations (1)
- National Pediatric Myoclonus Center, Department of Neurology, SIU School of Medicine, 751 N Rutledge St, Springfield, Illinois, United States
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00244361 on ClinicalTrials.gov